Sermorelin peptide UK, supplied in 5mg and 10mg vials. High-purity GHRH(1-29) analogue for pituitary signalling, growth-hormone release and endocrine feedback research. For laboratory research use only.
Sermorelin peptide UK is Crown Peptides’ synthetic analogue of growth-hormone-releasing hormone 1-29, supplied in 5mg and 10mg vials for laboratory research into GHRH receptor pharmacology and pituitary signalling.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone, the region responsible for receptor activity. It is therefore used in endocrine research as a defined GHRH-receptor agonist.
Sermorelin research examines GHRH receptor pharmacology, pituitary somatotroph signalling, growth-hormone release and downstream endocrine feedback, with structure-activity studies mapping the receptor-active region of the GHRH(1-29) sequence in detail (Learn more). Its relatively short sequence allows researchers to study the active N-terminal region of GHRH without using the full endogenous peptide, alongside related growth-hormone-secretagogue peptides such as [CJC-1295 with DAC] and [Ipamorelin].
Research context: the Sermorelin research areas described above reflect laboratory, preclinical or published scientific investigation. They should not be interpreted as established therapeutic effects, medical claims or approved human uses.
Crown Peptides Sermorelin is supplied for controlled laboratory research with batch-specific analytical documentation. High-Performance Liquid Chromatography (HPLC) can assess chromatographic purity, while Mass Spectrometry provides molecular information used to support identity verification. The batch-specific Certificate of Analysis is the definitive source for the exact purity result, identity data and analytical specification of the material supplied.
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid analogue corresponding to the active N-terminal region of human GHRH, supplied by Crown Peptides in 5mg and 10mg vials.
What receptor does Sermorelin target in research?
It is studied through the growth-hormone-releasing hormone receptor.
What is Sermorelin researched for?
Research includes pituitary signalling, growth-hormone release, GHRH receptor pharmacology and endocrine feedback.
Why is Sermorelin only 29 amino acids long?
The first 29 amino acids of GHRH contain the receptor-active region, allowing this shorter sequence to be studied independently.
How is Sermorelin tested?
HPLC and Mass Spectrometry can assess peptide purity and identity, with exact batch results recorded on the Certificate of Analysis.
Researchers working with Sermorelin may also be interested in [CJC-1295 with DAC], [CJC-1295 + Ipamorelin], [Ipamorelin], [GHRP-6] and [Tesamorelin] — other growth-hormone-secretagogue peptides studied in related research areas.
Each batch undergoes internal analytical verification using chromatographic and spectrometric methods prior to lyophilisation.
• HPLC Analysis
• Mass Spectrometry Confirmation
• Batch Traceability
By purchasing this product you confirm that you are a qualified researcher and that this compound will be used exclusively for laboratory research purposes.
This product is not intended for diagnostic or therapeutic use.
Any human or medical use is strictly prohibited.
Store in a cool, dry, secure and sterile environment away from any unauthorised persons or children.